Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Bladder Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Bladder Cancer

Expert Opinion / Cases · August 18, 2021

Newly Diagnosed Multiple Papillary Urothelial Tumors With Hydronephrosis

Written by
Brian T. Halbert MD, MPH


Discuss This item Follow

No comments yet, be the first to start the discussion!

  • Guru Sonpavde

    Aug 26, 2021

    This is a 78 year old woman with high-grade T1 urothelial bladder cancer with repeat TURBT showing pTa disease with lower ureter involved. The retroperitoneal lymphadenopathy (LN) is suspicious for metastatic disease. I would complete staging to assess the lung with a CT chest. Assuming no other suspicious lesions, I would biopsy the retroperitoneal LN to guide therapy (a PET scan may inform this decision although I prefer a definitive biopsy given the probability an elderly patient may concurrently have a low grade lymphoma causing lymphadenopathy). 
    Assuming the LN is proven metastatic, the next question is- is she cisplatin-eligible? If cisplatin-eligible, I would advise gemcitabine-cisplatin (GC) or dose dense MVAC, given the potential for cure. If the patient is not a candidate for cisplatin but has proven metastasis in the LN, I would suggest carboplatin (I personally prefer split dose weekly cisplatin if CrCl 40 to <60) plus gemcitabine. Following 4-6 cycles of platinum-based chemotherapy, I would offer switch maintenance Avelumab if she exhibits stable/responding disease, which is established by a phase III trial (Javelin Bladder-100).  If cisplatin-ineligible, first-line pembrolizumab or atezolizumab may be considered if tumor PD-L1 expression is high. However, the first-line PD1/L1 inhibitor approach does not have phase III trial data to support it.
    Given the oligometastatic clinical picture, I would consider SBRT (stereotactic body radiotherapy) to the LN metastasis after completing the chemotherapy and before Avelumab starts. I would also consider radiating the bladder with curative intent potentially with concurrent chemotherapy (following the chemotherapy and before Avelumab initiation) if the patient exhibits a satisfactory performance status and is willing to pursue an aggressive approach.
    The role of radical surgery in this setting of metastatic disease is unproven. However, in a young and fit patient, I would consider radical surgery (instead of radiation to the bladder mentioned above).
    Tumor genomic profiling should be performed in patients with metastatic disease to guide future therapy, especially with erdafitinib, an FGFR inhibitor. 
    If the retroperitoneal LN is not metastatic urothelial carcinoma, I would pursue neoadjuvant cisplatin-based combination chemotherapy followed by radical surgery (probably radical cystectomy + ureterectomy/nephroureterectomy). Following surgery, if high-risk muscle-invasive disease is seen, I would offer adjuvant nivolumab, which is supported by improved DFS seen in the CHECKMATE274 trial leading to US FDA approval. 
    Clinical trials should be strongly considered at every stage of the disease.

  • Apr 12, 2024

    Pending Moderator approval.

Further Reading